Important Submission Information
July 2023
The following information provides details on effective dates and deadlines for submitting Drug Product submissions to the Alberta Drug Benefit List (ADBL) for 2023 - 2024.
The following dates may be subject to change; however, you will be notified accordingly if such a change occurs.
Deadlines for Expedited Reviews of Biosimilars, Select Devices and Interchangeable Drug Products
| ADBL Effective Date | Deadlines for Complete Submissions |
|---|---|
| September 1, 2023 | July 25, 2023 |
| October 1, 2023 | August 25, 2023 |
| November 1, 2023 | September 25, 2023 |
| December 1, 2023 | October 25, 2023 |
| February 1, 2024 | November 28, 2023 |
| March 1, 2024 | January 25, 2024 |
| May 1, 2024 | March 25, 2024 |
| June 1, 2024 | April 25, 2024 |
| July 1, 2024 | May 24, 2024 |
| August 1, 2024 | June 25, 2024 |
| September 1, 2024 | July 25, 2024 |
| October 1, 2024 | August 26, 2024 |
Deadlines for all other Drug Product Submission Categories
| ADBL Effective Date | Deadlines for Complete Submissions |
|---|---|
| September 1, 2023 | June 9, 2023 |
| November 1, 2023 | August 10, 2023 |
| February 1, 2024 | October 10, 2023 |
| March 1, 2024 | December 11, 2023 |
| May 1, 2024 | February 9, 2024 |
| July 1, 2024 | April 10, 2024 |
| September 1, 2024 | June 10, 2024 |
| November 1, 2024 | August 9, 2024 |
Manufacturers should note that only complete submissions, satisfying all the submission requirements of the applicable category of Drug Product received by 4:30 p.m. Mountain Standard / Daylight Savings Time (as applicable) on the deadline, will be put forward for consideration by the Expert Committee on Drug Evaluation and Therapeutics or Expedited Review, as applicable. There is no guarantee that every completed submission will be reviewed and/or a recommendation made at the next scheduled meeting of the Expert Committee.
Alberta Price Confirmation Tentative Dates
The Alberta Price Confirmation (APC) is issued prior to an ADBL publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.
| ADBL Effective Date | APC Tentative Issue Date |
|---|---|
| November 1, 2023 | October 3, 2023 |
| December 1, 2023 | November 1, 2023 |
| February 1, 2024 | December 6, 2023 |
| March 1, 2024 | February 1, 2024 |
| April 1, 2024 | February 16, 2024 |
| May 1, 2024 | April 4, 2024 |
| June 1, 2024 | May 3, 2024 |
| July 1, 2024 | May 31, 2024 |
| August 1, 2024 | July 3, 2024 |
| September 1, 2024 | August 1, 2024 |
| October 1, 2024 | September 3, 2024 |
| November 1, 2024 | October 3, 2024 |
| December 1, 2024 | November 1, 2024 |
Correspondence
Manufacturers may provide submissions for consideration for potential addition to the Alberta Drug Benefit List (ADBL) via email to the following address: submissions@ab.bluecross.ca
Submissions sent to other email addresses will not be considered for potential addition to the ADBL. It is recommended that manufacturers place the drug name(s) and strength(s) of the submitted product(s) in the subject header in order to ensure that multiple emails can be easily associated with one another.
Manufacturers are reminded that hard copies of submissions must follow by mail and should be sent to the attention of:
Manager
Scientific and Research Services
Alberta Blue Cross®
10009 – 108 Street NW
Edmonton AB T5J 3C5
A copy of covering correspondence and summary documents only should be forwarded to:
Executive Director
Pharmaceutical Funding and Guidance
Alberta Health
11th Floor, 10025 Jasper Avenue
Edmonton AB T5J 1S6
Questions or Comments
Questions or comments regarding the drug review process or submission deadlines can be addressed to:
Coordinator
Scientific and Research Services
Alberta Blue Cross®
10009 – 108 Street NW
Edmonton AB T5J 3C5
Phone: 780-498-8098
Fax: 780-498-3534
Email: submissions@ab.bluecross.ca
Notice:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross® who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL (iDBL), and any such changes to the Interactive DBL (iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.